60 Degrees Pharmaceuticals, Inc. SXTP PHARMA
Company Overview
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Why Investors Should Care
Revenue has grown at a 65.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $1.01M (+65.5% YoY); net profit $-7.37M.
- Trailing 12 Months Year-on-year growth — revenue -32.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 65.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 65.15% |
| 1 Year: | -32.50% |
Stock Price Performance
| 1 Year: | -81.91% |
| 6 Months: | -49.39% |
| 3 Months: | -31.69% |
| 1 Month: | -12.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 65.1% over 5 years.
CONS
- Trading 86.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SXTP 60 Degrees Pharmaceuticals, Inc. PHARMA | 0.98 | -0.37 | $3.45M | 0.00% | - | - | 65.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.17K | 168.19K | 17.17K | 59.53K | 51.19K | 105.67K | 124.97K | 135.29K | - | 163.55K | 100.93K | 437.60K | 303.38K | 162.09K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 73.27K | 50.05K | 537.69K | 120.68K | 85.72K |
| Gross Profit | - | - | -55.95K | -124.44K | -20.01K | 40.24K | 35.41K | 23.61K | - | 90.28K | 50.88K | -100.09K | 182.70K | 76.38K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 2.00M | 1.66M | 2.23M | 2.10M | 2.17M |
| Operating Income | -686.92K | -215.12K | -950.66K | -788.00K | -1.52M | -1.34M | -4.19M | -2.12M | - | -1.91M | -1.60M | -2.33M | -1.92M | -2.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | -1.86M | -1.71M | -2.29M | -1.41M | -2.06M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.79K | 1.22K | 1.71K | 3.09K | 1.39K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -1.88M | -1.73M | -2.32M | -1.44M | -2.09M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 1.50K | 250 | -1.81K | 0 |
| Net Income | -2.15M | -1.45M | -2.60M | -3.34M | 4.18M | 430.47K | -4.17M | -2.16M | - | -1.88M | -1.73M | -2.32M | -1.44M | -2.09M |
| Diluted EPS | -0.96 | -0.61 | -1.13 | -16.84 | 9.13 | 1.83 | -21.12 | -2.92 | - | -6.25 | -5.00 | -2.52 | - | -1.28 |
| R&D Expense | 231.39K | 27.66K | 123.99K | 203.87K | 263.70K | 337.18K | 3.10M | 940.06K | - | 370.81K | 249.88K | 809.78K | - | 281.46K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 223.21K | 253.57K | 607.57K | 1.01M |
| Cost of Revenue | - | 432.37K | 474.55K | 384.76K | 781.70K |
| Gross Profit | - | -209.16K | -220.98K | 222.81K | 223.78K |
| Operating Expenses | - | 1.54M | 4.93M | 9.94M | 7.98M |
| Operating Income | - | -1.75M | -5.15M | -9.72M | -7.76M |
| EBITDA | - | -2.11M | -1.43M | -7.88M | -7.28M |
| Interest Expense | - | 3.99M | 2.29M | 7.91K | 7.80K |
| Pretax Income | - | -6.18M | -3.81M | -7.96M | -7.37M |
| Tax Provision | - | 500 | 250 | 0 | 0 |
| Net Income | - | -6.18M | -3.77M | -7.95M | -7.37M |
| Diluted EPS | - | -266.38 | -236.72 | -74.17 | -11.73 |
| R&D Expense | - | 525.56K | 691.77K | 4.99M | 2.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.30M | 7.78M | 5.76M | 5.37M |
| Current Assets | - | 1.10M | 7.24M | 5.39M | 4.90M |
| Cash & Equivalents | - | 264.87K | 2.14M | 1.66M | 1.51M |
| Inventory | - | 518.58K | 466.17K | 442.76K | 656.92K |
| Receivables | - | 45.97K | 231.33K | 486.75K | 509.64K |
| Total Liabilities | - | 25.45M | 2.99M | 1.80M | 1.99M |
| Current Liabilities | - | 23.92M | 2.84M | 1.66M | 1.84M |
| Long Term Debt | - | 1.27M | 150.25K | 147.12K | 144.00K |
| Total Debt | - | 22.42M | 172.67K | 155.89K | 152.78K |
| Total Equity | - | -23.58M | 4.87M | 4.04M | 3.46M |
| Shares Outstanding | - | 23.21K | 24.21K | 141.73K | 1.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.01M | -4.54M | -5.65M | -6.85M |
| Investing Cash Flow | - | -60.13K | -115.89K | -1.89M | 254.92K |
| Financing Cash Flow | - | 1.22M | 6.47M | 7.05M | 6.44M |
| Capital Expenditure | - | -60.13K | -115.89K | -181.11K | -218.08K |
| Free Cash Flow | - | -1.07M | -4.66M | -5.83M | -7.07M |
| Net Change in Cash | - | 151.59K | 1.82M | -483.63K | -156.41K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -93.7% | -87.1% | 36.7% | 22.3% |
| Operating Margin % | - | -784.2% | -2,032.8% | -1,599.0% | -771.6% |
| Net Margin % | - | -2,769.5% | -1,485.1% | -1,308.0% | -732.5% |
| ROE % | - | 26.2% | -77.3% | -196.9% | -212.7% |
| ROCE % | - | 7.7% | -104.2% | -236.8% | -220.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kathmere Capital Management, Llc | 7.54% | 265.10K | $253.44K |
| 2 | Citadel Advisors Llc | 0.64% | 22.36K | $21.38K |
| 3 | Xtx Topco Ltd | 0.50% | 17.64K | $16.86K |
| 4 | Kovack Advisors, Inc. | 0.43% | 15.00K | $14.34K |
| 5 | Geode Capital Management, LLC | 0.41% | 14.55K | $13.91K |
| 6 | UBS Group AG | 0.39% | 13.59K | $12.99K |
| 7 | Barclays Plc | 0.03% | 1.05K | $1.00K |
| 8 | Osaic Holdings Inc. | - | 25 | $23 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SXTP
60 Degrees Pharma flags going-concern risk - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVkNpajdTQ1ZqcmFLaHFIV0p2UG1kd3ByeDZzMmo4bW5nMGdDUUlhLTlnVE5zVUEwNlV4aXU3MHpqZXl3cFh1OTAxamc2U0UzeHNXTEVBVVpCY0R1MFVPQkNhV25zYVctNHBQbzByWmNfWWkxMy1QVm8wZFhRa29GRnNfX2pWbzBRNm5nbj…
SXTP - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9EemNSTW1oWmxtTVhrU0pKQU40UGtvTHRSSWdJMHN0U3gwbEQ4YmhTOW1IMXl2aXJTYzQ0TjJzclJsdUdRaFE?oc=5" target="_blank">SXTP</a> <font color="#6f6f6f">Finviz</font>…
A pharmaceutical company will post a public presentation Sept. 11. Its management will meet investors in New York. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQUGtUeGtJWTFfV0Mtdnl0NE1FTHpYM0I2WlZQaGtPa2V3U1ZlOGQzTkNOX3hCRUpiaG1WMFVNVzRHWkVnY3ZiSmFEWW80YWhRc2cyYWcwZjJsZE9wUEZMRGJEbk9HZ2xEcThRVlpFYjVzY0NvVzRtQ0tTa29sY0dURGlPTjE2aUs1NG1Scl…
SXTP Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBrXzlvVU5IVlJfdVBGOVFxc3NDS2cwaENlOG01dG1lZ2dDTkpKeXdaMDJrSzlEQlBsNVdGS3lDMDYyOXBCMUJaaGhDUjZBNVRyeWZROUFfRnFORXg5Zjd1N1dGYUxObDhwa1lqX0dCTFIzcGhMcHRNSjR3?oc=5" target="_blank">SXT…
SXTP Stock Rockets 161% Pre-Market — What Is Driving The Surge? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNSkhtVVRnLU9oRmp5YmNVbllQS0dWSXp6OGx6VUx1Z2EzenZxcjlQX1B1Z0lISUxJc0lIVjNJVXFuNVlzaVpDZHFVQWR5QUtTMmVmOC1HY3M4ZWVBTlFfdmx2TFl0S3dPT0JUVlI4UWRTV19mdjQzX1JqNWVoM1hhLWlBbHN1T1gtQ2lzcW…
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOemlsUHY1UkYxWUhHRzhFZU84UDMwb1pVY1lrQWlvdUpFdXhja1FvZXpMdzYzWmI0RjhTTXZzLXotS0ZrUmNuTjFScnJQZnd1akdGRDJMRTFXUmJ0a0ZIRGR5UkljRnBoZjRBdlV4SXZ2NEpJUTVEUEFqLTRROS1US1VoLWgyUkFMNmZxNH…
SXTP — Frequently Asked Questions
What is the current share price of 60 Degrees Pharmaceuticals, Inc. (SXTP)?
As of 2026-09-19 21:16 PDT, 60 Degrees Pharmaceuticals, Inc. (SXTP) trades at $0.98 on NasdaqCM. Its 52-week range is $0.92 to $7.20.
What is the market capitalisation of SXTP?
60 Degrees Pharmaceuticals, Inc. (SXTP) has a market capitalisation of $3.45M on NasdaqCM.
What is the P/E ratio of SXTP?
SXTP trades at a trailing price-to-earnings (P/E) ratio of -0.37. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.37.
Is SXTP a good stock to buy?
This page provides a data-driven analysis of 60 Degrees Pharmaceuticals, Inc. (SXTP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.